Hoth Therapeutics, Inc., a biopharmaceutical company focused on developing innovative therapies, announced that it has entered into an exclusive patent license agreement with the US Department of Veterans Affairs (VA). This agreement provides Hoth with exclusive rights to a jointly owned patent portfolio co-developed by the VA and Emory University.
The licensed technology centres on ""Glial Cell Line-Derived Neurotrophic Factor, Obesity, and Obesity-Related Diseases and Conditions,"" a groundbreaking innovation aimed at addressing critical challenges in treating obesity and associated health conditions. This agreement underscores Hoth Therapeutics' commitment to advancing transformative healthcare solutions.
Under the terms of the agreement, Hoth Therapeutics will have exclusive rights to develop, market, and commercialize products and processes derived from the licensed patents. The VA and Emory University have granted Hoth this license to further develop the technology with the goal of ensuring the benefits of this innovation are accessible to the widest audience possible.
""We are honoured to collaborate with the VA and Emory University to bring this cutting-edge technology to market,"" said Robb Knie, chief executive officer of Hoth Therapeutics. ""This partnership represents a significant milestone in our efforts to address obesity and related health conditions with innovative, science-driven solutions. We look forward to advancing this critical work to improve the lives of patients worldwide.""
The agreement includes a comprehensive development plan, ensuring the continued progress of this technology from the research phase through commercialization. Hoth Therapeutics plans to leverage its expertise and resources to bring the licensed products to the point of practical application while adhering to rigorous development benchmarks.
This collaboration exemplifies Hoth's dedication to fostering partnerships that advance scientific discoveries into therapeutic solutions. The company remains steadfast in its mission to improve patient outcomes and address unmet medical needs.
Hoth has also entered into an agreement to further protect its intellectual property by signing an LOI to acquire additional provisional patent protection for its lead therapeutic HT-001. The additional intellectual property expands HT-001's reach to other cancer therapeutics.
Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!